EN DE
Watch Macrogen Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Macrogen Inc (038290) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Macrogen Inc stock KRW 4,457, price KRW 11,000, that is 59.5% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7038290003

MI Macrogen Inc logo Some data Nov 8, 2026

Macrogen Inc

038290 · KQ
Very expensive, weak quality

Our calculation puts a fair price 59% below what the stock costs today.

Low debt
Generates free cash flow over the last twelve months
Revenue last quarter +25% vs. a year ago.
Quality 49/100
Expensive Growth (revenue 5y +11.6 %/yr in KRW)
Thin margins · 1.6% net margin (TTM)
1.9% dividend yield · Safety not assessed
Some data
Fair value 4,457 KRW · Strongly overvalued
Trails peers (4/11)
Narrow moat 22/100 · thin data
Watch Macrogen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

36,122 KRW 10,700 KRW Fair Value 4,457 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 10,700 KRW – 36,122 KRW · fair‑value band 3,342 KRW – 5,571 KRW · the 11,000 KRW price screens above the 4,457 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow Macrogen in your weekly email

Every Wednesday you see whether Macrogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally.

Show moreShow less

It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services.

The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services.

In addition, it offers genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance.

Further, the company provides covid-19 test kit under the Axen name, as well as operates smart mobile lab for covid-19 testing. Additionally, it offers iD4U genetic testing services for kinship and personal identification; and myPETGENE genetic testing service for pets.

Macrogen, Inc. was founded in 1997 and is headquartered in Seoul, South Korea.

Stock analysis

Macrogen Inc (038290) currently trades at 11,000 KRW, while our model-based Fair Value estimate is 4,457 KRW, 59% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 7,053 KRW per share, and 1 of the 14 models we run sit above the 11,000 KRW price.

Bear case: the Dividend Discount group reads lowest at 1,654 KRW, and 13 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 3,342 KRW (bear) to 5,571 KRW (bull), the price of 11,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Macrogen Inc reported revenue of 195B KRW in FY2025 versus 129B KRW in FY2021, a compound +10.9%/yr. Reported net income was 2.0B KRW in FY2025, compounding +16.2%/yr from FY2021.

Key figures

Market cap 119B KRW (≈ $88.2M) Micro · P/S ratio 0.88 · Dividend yield 1.9% · Net margin 1.6% · Return on equity −502% · Return on assets (EBIT) −1.7% (5-year average) · Operating margin 3.3% · Revenue (TTM) 138B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at −59%, 038290 screens richer than that median.

Fair Value models

Bear 3,342 KRW Fair Value 4,457 KRW Bull 5,571 KRW
Price 11,000 KRW · Downside -59.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 8,270 KRW 8,815 KRW 9,622 KRW 76
EPV 1,510 KRW 1,513 KRW 1,516 KRW 73
ROIC Compounder 1,510 KRW 1,513 KRW 1,516 KRW 71
All 14 models by family
Earnings-Based
Graham-Dodd 1,377 KRW 5,946 KRW 8,128 KRW 64
Lynch FV 1,526 KRW 2,180 KRW 2,834 KRW 61
PEG = 1.0 1,526 KRW 2,180 KRW 2,834 KRW 57
EPV 1,510 KRW 1,513 KRW 1,516 KRW 73
Dividend Discount
Gordon GGM 1,034 KRW 1,688 KRW 2,150 KRW 69
DDM Multi-Stage 1,034 KRW 1,621 KRW 1,820 KRW 67
Multiples
P/E Multiple 3,342 KRW 4,457 KRW 5,571 KRW 63
P/S Multiple 2,583 KRW 3,444 KRW 4,305 KRW 57
P/B Multiple 16,406 KRW 21,875 KRW 27,344 KRW 55
EV/EBITDA 6,733 KRW 9,650 KRW 12,566 KRW 66
Asset-Based
NCAV (Graham) 3,238 KRW 4,906 KRW 6,133 KRW 54
Economic Profit
Residual Income 8,270 KRW 8,815 KRW 9,622 KRW 76
ROIC Compounder 1,510 KRW 1,513 KRW 1,516 KRW 71
Growth Earnings
Growth-Adj P/E 2,615 KRW 3,736 KRW 4,856 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 88
Are margins and returns getting better?
Cashflow 37
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 56
Does it invest with discipline instead of growing at any price?
Low Volatility 68
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+43.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +9.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−45.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−47.2%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−47.2% vs −9.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 0%
Pace: the 5-year rate starts in 2020 (pandemic)

038290 screens overvalued: fair value 59% below the price. Compare with MEDIPOST Co →

Compare Macrogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2276 stocks

Beats the sector median on 4/11 measures
Overall it trails its sector peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −59.5% · Below median
Profitability
Return on assets 1.2% · Below median
Net margin (12 months) 3.4% · Below median
Operating margin (12 months) 3.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 24.9% · Top 25%
Dividend yield (12 months) 1.9% · Above median
Balance sheet
Debt / equity 0.10× · Above median

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 0.76× · Cheapest 25%
P/S (12 months) 1.82× · Cheaper than median
EV/EBITDA 14.2× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 18
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)38 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Purple Biotech Ltd KTOV 0.0100 ILS 0.0160 ILS +60% vs 038290
Cell Biotech Co 049960 14,630 KRW 15,078 KRW +3% vs 038290
AbbVie Inc ABBV $291.31 $259.62 −11% vs 038290
Biotoxtech Co 086040 2,185 KRW 1,916 KRW −12% vs 038290
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs 038290
Bioneer Corporation 064550 6,350 KRW 3,547 KRW −44% vs 038290
Eli Lilly and Company LLY $1,354 $749.92 −45% vs 038290
Panagene Inc 046210 1,071 KRW 480.36 KRW −55% vs 038290
MEDIPOST Co 078160 8,480 KRW 3,576 KRW −58% vs 038290
Pluri Inc PSTI 3.99 ILS 0.9600 ILS −76% vs 038290

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Macrogen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Macrogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/038290

Frequently asked questions

Is Macrogen Inc (038290) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 4,457 KRW versus a price of 11,000 KRW, about 59% lower (overvalued).
What is the fair value of 038290?
Our model-based fair value for Macrogen Inc is 4,457 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 11,000 KRW.
What is the quality score of 038290?
Macrogen Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Macrogen Inc (038290)?
Our model-based price target is the fair value of 4,457 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 3,342 KRW, optimistic scenario 5,571 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Macrogen Inc stock forecast for 2026?
Our models put fair value at 4,457 KRW, about 59% lower versus a price of 11,000 KRW (overvalued). Cautious scenario 3,342 KRW, optimistic scenario 5,571 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Macrogen Inc (038290)?
Macrogen Inc reported trailing-twelve-month revenue of about 138B KRW (latest available figure, as of Nov 8, 2026).
Does Macrogen Inc pay a dividend?
Macrogen Inc currently shows a dividend yield of 1.90% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Macrogen Inc (038290)?
Macrogen Inc has a dividend yield of 1.9%. A dividend has been paid every year since at least 2020. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What is the intrinsic value of Macrogen Inc (038290)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Macrogen Inc it is 4,457 KRW per share (as of Nov 8, 2026), against a price of 11,000 KRW. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Macrogen Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 038290 trades above its calculated fair value: price 11,000 KRW, fair value 4,457 KRW, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 038290?
No. The price is what the market pays today (11,000 KRW); the fair value is what the company's own numbers justify (4,457 KRW). For Macrogen Inc the two are 6,543 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Macrogen Inc worth?
The market values Macrogen Inc at about 119B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 11,000 KRW; our models calculate a fair value of 4,457 KRW per share.
What do the bullish and bearish scenarios say about 038290?
Our models span a range for Macrogen Inc: cautious scenario 3,342 KRW, base 4,457 KRW, optimistic 5,571 KRW per share (as of Nov 8, 2026, price 11,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Macrogen Inc (038290)?
Balance-sheet figures for Macrogen Inc (as of Nov 8, 2026): debt of 0.10 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 038290 from its 52-week high?
Macrogen Inc trades at 11,000 KRW, about 44% below its 52-week high of 19,520 KRW and 3% above the low of 10,700 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4,457 KRW is for.
Which stocks are comparable to Macrogen Inc?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Cell Biotech Co, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Macrogen Inc stock attractive at the current price?
The data as of Nov 8, 2026: price 11,000 KRW, calculated fair value 4,457 KRW (−59%), Quality Score 49/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 038290 calculated?
We run Macrogen Inc through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4,457 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Macrogen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Macrogen Inc (038290)?
The closing price on Nov 6, 2026 was 11,000 KRW. Our model-based fair value is 4,457 KRW, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Macrogen Inc right now?
The price sits above even our optimistic bull case (5,571 KRW). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Macrogen Inc

How large is the market capitalisation of Macrogen Inc (038290)?
The market capitalisation of Macrogen Inc is 119B KRW (≈ $88.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Macrogen Inc (038290)?
The price-to-sales ratio of Macrogen Inc is 0.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Macrogen Inc (038290)?
The dividend yield of Macrogen Inc is 1.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Macrogen Inc (038290)?
The net margin of Macrogen Inc is 1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Macrogen Inc (038290)?
The return on equity (ROE) of Macrogen Inc is −502% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Macrogen Inc (038290)?
On an EBIT basis the return on assets of Macrogen Inc is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Macrogen Inc (038290)?
The operating margin of Macrogen Inc is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Macrogen Inc (038290)?
Revenue at Macrogen Inc is growing +24.9% versus a year earlier (3y avg +12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Macrogen Inc (038290)?
Earnings per share at Macrogen Inc are growing +621% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Macrogen Inc (038290) generate?
The free cash flow of Macrogen Inc is −13.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Macrogen Inc (038290) carry?
The net debt of Macrogen Inc is 42.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Macrogen Inc in the live analysis

One click puts Macrogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.